核苷类药物靶向制剂的研究进展

本文ID：140943

论文字数:7689

论文编号：YaoX231 论文字数:7689，附开题报告

摘要

研究表明核苷类药物对病毒、肿瘤等都具有良好的治疗效果，但单纯的核苷类药物具有作用选择性差, 毒副作用大等缺点。而靶向制剂是以药物能在靶区浓集为主要特点的一大类制剂的总称,其给药后最突出的特点是利用药物载体系统将治疗药物最大限度地运送到靶区, 使治疗药物在靶区浓集超出传统制剂的数倍乃至数百倍, 治疗效果明显提高。因此靶向技术用于核苷类抗病毒药物, 可有效增加该类药物的作用选择性, 降低毒副作用，增强治疗效果。目前研究中的核苷类药物靶向制剂包括被动靶向制剂、主动靶向制剂、物理化学靶向制剂、生物免疫靶向等。本文拟对核苷类靶向制剂的研究进展进行综述。

核苷类药物靶向剂的研究进展····················································2

前言 ··················································································4

1.被动靶向·············································································5

1.1脂质体········································································5

1.2纳米粒········································································5

1.3微球···········································································6

1.4药质体········································································7

2主动靶向·············································································8

2.1半乳糖受体介导····························································8

2.2 PSA介导·····································································8

2.3 TNP( 三硝基苯基)-抗生物素蛋白链菌素介导·······················8

3物理靶向··············································································9

3.1磁性靶向······································································9

3.2温度靶向······································································9

3.3 PH值靶向····································································9

4生物靶向··············································································10

4.1分子靶向······································································10

4.2单克隆抗体靶向·····························································10

4.3多重靶向······································································10

结语·······················································································11

参考文献·················································································12

致谢·······················································································14